Epidermal growth factor receptor expression and gene copy number in sinonasal intestinal type adenocarcinoma

Oral Oncology

Volumn 45, Issue 9, 2009, Pages 835-838

  Franchi, Alessandro ^a   Fondi, Cristina ^a   Paglierani, Milena ^a   Pepi, Monica ^a   Gallo, Oreste ^a   Santucci, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adenocarcinoma; EGFR; Fluorescent in situ hybridization; Immunohistochemistry; Intestinal type; Nose and paranasal sinuses; Occupational

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARPENTER; CHROMOSOME 7P; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISOMY; DISTANT METASTASIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE REPLICATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LEATHER INDUSTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL HAZARD; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINONASAL INTESTINAL TYPE ADENOCARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE DOSAGE; GENES, ERBB-1; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NOSE NEOPLASMS; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PARANASAL SINUS NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; WOOD;

EID: 68949216609     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.12.005     Document Type: Article

References (18)

1. Franchi A., Santucci M., and Wenig B. Adenocarcinoma. In: Barnes L., Eveson J.W., Reichart P., and Sidransky D. (Eds). World Health Organization classification of tumours. Pathology and genetics of head and neck tumours (2005), IARC, Lyon 20-23
2. Llorente JL, Pérez-Escuredo J, Alvarez-Marcos C, Suárez C, Hermsen M. Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review. Eur Arch Otorhinolaryngol 2008;Jun 17.
3. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 22 (2004) 337-345
4. Saltz L.B., Meropol N.J., Loehrer P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
5. Goldstein N.S., and Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92 (2001) 1331-1346
6. Hemming A.W., Davis N.L., Kluftinger A., et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 51 (1992) 147-152
7. Spano J.P., Fagard R., Soria J.C., et al. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 16 (2005) 189-194
8. Macarenco R.S., Uphoff T.S., Gilmer H.F., Jenkins R.B., Thibodeau S.N., Lewis J.E., et al. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol 21 (2008) 1168-1175
9. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur J Cancer 37 (2001) S9-15
10. Pinter F., Papay J., Almasi A., Sapi Z., Szabo E., Kanya M., et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn 10 (2008) 160-168
11. Buckley A.F., Burgart L.J., Sahai V., and Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 129 (2008) 245-251
12. Artega C.L. Tumour EGFR expression: assessment and implications. Signal 3 (2002) 4-8
13. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., and Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
14. Cappuzzo F., Finocchiaro G., Rossi E., Jänne P.A., Carnaghi C., Calandri C., et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19 (2008) 717-723
15. Italiano A., Follana P., Caroli F.X., Badetti J.L., Benchimol D., Garnier G., et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 15 (2008) 649-654
16. Hirsch F.R., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18 (2007) 752-760
17. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;Sep 18 [Epub ahead of print].
18. Licitra L., Suardi S., Bossi P., Locati L.D., Mariani L., Quattrone P., et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol 22 (2004) 4901-4906